Supplemental Materials

Extended Methods

Human Samples

This study was carried out following the Declaration of Helsinki, was approved by the Research Ethics Committee of the University of Southern Santa Catarina (UNISUL) under 34681920.8.0000.5369 (for Preeclampsia samples - approved in 20/08/2020) or CAAE: 36084720.9.0000.5369 (for cardiac defects - approved in 18/01/2021) and all participants signed written informed consent and collected samples have been anonymised.

Animals

Female C57/Bl6J mice and male Balb/C mice were purchased from Charles River UK. CD45.1 (B6.SJL-Ptprca Pepcb/BoyJ) were originally purchased from Charles River Italy and C57BL/6-Tg(CAG GFP)131Osb/LeySopJ mice from The Jackson Laboratory, respectively. CCR2-deficient (B6.129S4-Ccr2tm1Ifc/J; JAX stock #004999)(Boring et al., 1997) were originally purchased from Jackson laboratory but were provided as a generous gift from Dr Gerard Graham, University of Glasgow. All mice were housed at the animal facility of Queen Mary University of London and were conducted with strict adherence to the Home Office guidelines (PPL P71E91C8E) following approval by the Animal Use and Care Committee of Queen Mary University of London (QMUL). Mice used in the experiments of this study, unless specified were used at 8-12 weeks old

Timed-mated allogeneic pregnancy

Timed mating was performed by housing Balb/C male mice with aged-matched female C57BL/6J or CD45.1 mice overnight and confirmed by the presence of a copulatory plug the following morning; this was defined as day 1 or mouse embryonic stage 0.5 (E0.5). Circulating maternal neutrophils were depleted at days 5 (E4.5) and 8 (E7.5) of pregnancy using a monoclonal neutralizing antibody (Biolegend, clone 1A8; 50 µg

i.v.) or isotype control (Biolegend clone RTK2758; 50µg i.v). Following neutrophil depletion, some mice were injected with anti-mouse TNF- α i.v (Biolegend clone MP6-XT22; 10mg/kg i.v) on day 9 of pregnancy. Pregnant females were sacrificed at either day 15 of gestation (E14.5) or left to give birth and offspring were sacrificed at post-natal day 5 (P5) or post-natal day 28 (P28).

In vivo BrdU uptake

Mice were injected with 100mg/kg 5-Bromo-2'-deoxyuridine (BrdU) i.v (Sigma; B5002-1G) and culled 1 hour later. Single cell suspension were prepared from the required organs and stained with FITC BrdU staining kit (Invitrogen; 8811-6600-42) according to the manufacturer's instructions.

Transfer of GFP⁺ leukocytes into pregnant females

5X10⁶ Splenic leukocytes from GFP⁺ age-matched females were injected intravenously into either isotype or NDPI pregnant females. 18 hours after injections, pregnant mice were culled and detection of GFP⁺ leukocytes within the placentas and E14.5 embryonic hearts via flow cytometry and immunofluorescence.

Placenta permeability assay using FITC dextran

To test the permeability of placentas, 10mg/ml of FITC-dextran in PBS (20,000 mW, Sigma Aldrich) was injected intravenously in pregnant isotype control or NDPI mice for 15 minutes. Mice were then culled, and placentas were immediately fixed in 4% paraformaldehyde for two hours followed by 70%ethanol, dehydrated in 30% sucrose, and embedded in OCT for imaging. Wide field imaging was carried out using Nanozoomer S60 slide scanner (Hamamatsu).

Placental neutrophil isolation and splenic monocyte in vitro co-culture

Placentas obtained from E14.5 pregnant mice were cut into small fragments and digested in 1XPBS with 20mM HEPES, 60 U/ml DNase I and 450 U/ml Collagenase I at 37°C and 250rpm for 20 minutes. Suspensions were passed through 70µm filters, washed and red blood cells lysed with ACK lysis buffer. Placental neutrophils contained in the resulting single cell suspension were enriched via positive selection using 0.2µg anti-mouse Ly6G PE (Biolegend, clone 1A8) per 1x10⁶ cells followed by

anti-PE microbeads (Biolegend), used according to the manufacturer's instructions. The enriched placental neutrophil population were then used in downstream applications.

Monocytes, from spleens of non-pregnant female C57BL/6J mice were isolated using a commercially available negative selection kit according to manufacturer's instructions (EasySep mouse monocyte isolation kit). 1x10⁵ placental neutrophils were co-cultured with 1x10⁵ splenic monocytes in DMEM (Gibco) growth media containing 10% FCS and 50 IU/mL penicillin, 50 μg/mL streptomycin and supplemented with 10ng/ml M-CSF (Biolegend; cat#576402) at time of culture and again at day 3 of culture. Cells were cultured for a total of 5 days.

Flow cytometry and antibodies

Single cell suspensions were prepared E14.5 embryo hearts, E14.5 embryo livers and P5 hearts through $70\mu m$ cell strainers. For placentas (see neutrophil isolation methods) and P28 hearts, enzymatic digestion was used to obtain single cell suspensions. Briefly, P28 hearts were digested using 450U/ml Collagenase I, 125 U/ml Collagenase XI, 60U/ml Dnase1 in 1XPBS containing 20mM HEPES. In both cases, tissues were digested for 20 minutes, at 37C in a shaking incubator at 125 RPM.

Dead cells were excluded using a fixable viability dye LIVE/DEAD fixable aqua (Thermo Fisher Scientific, L34957). Cells were gated on singlets (See Figure S12). Cells were then further phenotype as indicated in the results. Representative FACS plots show initial gating strategy for singlets and live cells.

Immunofluorescence microscopy

Tissues were fixed in 4% paraformaldehyde for 2 hours and paraffin or OCT embedded. Paraffin embedded sections were de-paraffinised with Histoclear and rehydrated prior to antigen-retrieval performed by heating sections to 95°C for 10 min in Abcam antigen retrieval solution (ab64236). Sections were stained for hematoxylin/eosin or incubated with primary antibodies for immunofluorescence staining and mounted with Fluoromount G (Thermofisher 00-4958-02)

Nuclei were visualized using DAPI. Wide field imaging (bright field and immunofluorescence) was carried out using Nanozoomer S210 or S60 slide scanner

(Hamamatsu). Confocal microscopy was carried out on a Carl Zeiss LSM800. Images were analysed with ImageJ (NIH) and Volocity (Version 6.3, PerkinElmer).

High resolution episcopic microscopy (HREM)

Samples for high resolution episcopic microscopy (HREM) were fixed in Bouin's for a minimum of 12h followed by extensive washing in PBS, dehydration in graded methanol series, incubation in JB-4 (Sigma) /Eosine (Sigma)/Acridine orange (Sigma) mix overnight to ensure proper sample infiltration and then embedded in fresh mix by adding the JB4 accelerator. Once polymerized the block where imaged as previously described⁴⁶. Samples were sectioned on a Leica sledge microtome at 1 or 2 µm or on commercial oHREM (Indigo Scientific) at 0.85 or 1.7 µm. An image of the surface of the block was then acquired under GFP excitation wavelength light using Olympus MVX10 microscope and High-resolution camera (Jenoptik). After acquisition the stacks were adjusted for gray level using Photoshop CS6 and then process for isotropic scaling, ortogonal re-sectioning, 25% downscaling, using a mixture of commercial and homemade software (see Wilson R et al. NAR 2016, Vol. 44 D855-D861). 3D volume rendering of the datasets were produced from the 25% downscale stack using Horos. Quantification of number and length of LV trabeculae were measured using Fiji imaging software⁴⁷. Number of trabeculae were measured at the point of invagination within the endocardial wall and were made from 2D images obtained from the 3D rendering by two independent researchers.

Cytokine analysis

Placenta digest supernatants and plasma concentrations of TNF- α (Peprotech, 900-TN54) and IL-1 β (Biolegend, 432601) were measured by ELISA according to the manufacturer's instructions.

In Vivo Cardiac Functional Assessments

Echocardiography was performed on offspring at postnatal day 28 to assess cardiac structure and function using a Vevo-3100 imagining system (VisualSonics, Toronto, Ontario, Canada). Mice were anaesthetized (3% isoflurane in 0.2L/min oxygen, maintained with 2% isoflurane and 0.4L/min) and body temperature maintained at 37 °C. Heart rate was monitored for the duration of the procedure. Images from two-

dimensional brightness mode (B-mode) and one-dimensional motion mode (M-mode), were obtained. Left ventricular ejection fraction (EF%), fractional shortening (FS%), cardiac output and stroke volume measurements were obtained from short-axis M-mode. Values were averaged from three beats. Echocardiographic analyses were performed by two independent operators, using Vevo LAB dongle software V3.2.6.

Quantitative Real-time polymerase chain reaction

Placenta, fetal heart and fetal liver samples were stored in RNAlater (Invitrogen) at -80°C until processing. 30mg of placenta tissue was disrupted using a sample grinding kit (GE healthcare) and RLT buffer. Fetal heart and liver tissues were disrupted using a syringe and 25G needle and RLT buffer containing 2-Bme. RNA from the disrupted placental tissue and fetal heart and liver tissue was extracted using the RNeasy mini kit, according to the manufacturer's recommendations. RNA quality and quantity was assessed using absorption measurements (Roche, Nanodrop) prior to performing the reverse transcription reaction, as per the manufacturer's instruction (BioRad, iScript™ cDNA synthesis kit), qPCR was performed using 10ng cDNA, 1µM PCR primers (see table below for sequences) and 1x SYBR GreeN PCR mastermix (BioRad) in a CFX connect light cycler (BioRad). Expression was calculated according to the method whereby data is normalized to two housekeeping genes, HPRT and RPL32A. The thermal cycling conditions were 95°C for 30 seconds and 40 cycles of 95°C for 5 seconds followed by 60°C for 30 seconds and then melt curve analysis 95°C for 5 seconds, 65°C for 5 seconds and 95°C for 5 seconds. Experiments were performed in duplicate.

Bulk RNA sequencing

High-quality RNA was extracted from 3 individual placenta from. Each treatment group, isotype (control) and aLy6G (NDPI) using Qiagen RNA extraction kit (Qiagen, Germany) and submitted to Eurofins (Germany) for Illumina sequencing. All raw data has been deposited on Figshare (https://figshare.com/s/8b13463311cf442e9d15). Please see the analysis pipeline at github.com/kerrimalone/aLy6G_RNAseq. Briefly, read quality was assessed with FastQC (v0.11.9)(https://www.bioinformatics). Transcript quantification was performed using Salmon (v.0.14.2) and the *Mus musculus* reference transcriptome (GRCm38, Gencode, release M23)⁴⁸. Transcripts

were summarized at the gene level, genes displaying expression levels below one count per million (CPM) in at least 3 individual libraries were filtered out. Differential expression (DE) analysis was performed between NDPI and control using EdgeR ⁴⁹. A False-Discovery Rate (FDR) threshold (≤0.05, Benjamini-Hochberg) was set to define DE genes. Positive log2 fold change indicates that a gene is higher expressed in aLyG6-treated samples and vice versa. Cellular functions and pathways overrepresented for the DE gene list were assessed using the SIGORA in R⁵⁰.

Fetal heart CD45⁺ cell isolations

Hearts from fetuses at E14.5 were dissected and passed through a 70µm cell strainer to obtain a single cell suspension. Heart CD45⁺ cells were enriched via positive selection using 0.2µg anti-mouse CD45 PE (Biolegend, clone 30-F11) per 1x10⁶ cells followed by anti-PE microbeads (Biolegend), used according to the manufacturer's instructions. The enriched fetal heart CD45⁺ cells were subsequently used for single cell RNA sequencing.

Single cell sequencing

Fetal heart CD45 cells were fixed using 80% methanol and stored at -80°C according to a GENEWIZ-developed protocol. Upon shipping to the Genewiz facility cryopreserved cells were thawed, washed, and counted following the 10x Genomics protocol. Cell suspensions were loaded onto the 10x Genomics Chromium Controller targeting ~10,000 cells per sample for processing and microdroplet generation. The resulting libraries were sequenced with the Illumina® HiSeq and resulted in 52,874 reads on average per cell, per sample. Primary data analyses were conducted in R v4.0.3 following the analysis outlined strategy https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238499/. Raw BC count matrices were imported to Seurat v4 with min.cells 3 and min.features 400. Prior to normalization, each sample was downsampled randomly to 50000 cells. Each sample was then normalised via SCT transformation. Prior to integration, 2000 variable features were identified using selection.method 'vst'. For identifying integration anchors, 2000 anchor features were identified via the cca method - other parameters were idims 1:30, k.anchor 5, k.filter 200, and k.score 30. For the final integration, the following parameters were set: idims 1:30 and k.weight 100. Prior to downsteam analysis, cells with mitochondrial gene expression > 10% were filtered out, as were

those with nCount_RNA > 40000 and nFeature_RNA > 5000. Clusters were identified in the integrated data using default parameters for FindNeighbors and FindClusters. Markers for each cluster were identified using FindMarkers with parameters logfc.threshold 0.0, test.use 'LR', min.pct 0.25, and min.diff.pct -Inf. Markers per cluster, per treatment were identified using FindAllMarkers and parameters logfc.threshold 0.0, test.use 'LR', min.pct 0.0, and min.diff.pct = -Inf. Volcano plots were generated via EnhancedVolcano. Gene Set Enrichment Analysis was performed via fgsea. Gene Ontology (GO) and KEGG enrichment was performed with topGO and KEGGprofile, respectively. Gene enrichment was also performed using enrichR. Further plots were generated via scDataviz. Cluster annotations were identified using top expressed genes in each cluster as shown in heat map in figure S9 (see also table in Figure S10)

All raw data has been deposited on Figshare (https://figshare.com/s/98321569e7f6a15aff65 and https://figshare.com/s/83bf3f8ba06d4884d827).

Data availability


All RNA seq and Single cell-sequencing raw data can be found via Figshare:

https://figshare.com/s/8b13463311cf442e9d15

https://figshare.com/s/98321569e7f6a15aff65

https://figshare.com/s/83bf3f8ba06d4884d827

All other data are available upon request to the corresponding author




Control treated (white) and neutrophil depleted (NDPI) (pink).

- (A) Schematic for experimental design
- (B) Weights of E14.5 placentas.
- (C) Immunofluorescent staining of placentas for wheat germ agglutinin (WGA) (green) to show gross structure and cell nuclei with DAPI (blue). White dotted line indicates the separation of the labyrinthine zone/trophoblast area and the outer junctional zone. Graph showing the proportion of the total area of the placentas occupied by the trophoblast zone. Scale bar =2.5mm
 (D-F) Flow cytometry quantification of different leukocyte subsets in placenta, expressed as cell number per gram of tissue (D) CD45+ cells (E) CD3+ total T cells, NK1.1+ NK cells, (left to right) (F) F4/80+ Ly6chiTNF-α+ macrophages.
- (G) Proportion of F4/80+Ly6C-, F4/80+Ly6Chi and F4/80-Ly6Chi cells following *in vitro* co-culture of isolated neutrophils from isotype of NDPI placentas with naïve splenic monocytes from non-pregnant female mice
- (H) F4/80⁺Ly6C^{hi} and F4/80⁻Ly6C^{hi} co-cultures described in (G) were analysed for the expression of MHCII and CCR2, expressed as median fluorescent intensity.

Each symbol represents an individual mouse and statistical significance was tested by Student's unpaired t-test. ns = not significant, *p \leq 0.05, ** p \leq 0.01, ***p \leq 0.001 **** p \leq 0.0001. In all cases, data are mean \pm SEM. MFI, median fluorescence intensity


| Ensembl ID | Gene Symbol | Gene Name | Collagen Type | Adj P val | Log2FC |
|-----------------------|-------------|--------------------------------------------------|---------------|----------------|----------|
| ENSMUSG00000001506 | Col1a1 | collagen, type I, alpha 1 (Col1a1), mRNA | typeI | 3.27E-14 | 3.188074 |
| ENSMUSG00000029661 | Col1a2 | collagen, type I, alpha 2 (Col1a2), mRNA | typeI | 3.45E-13 | 2.874913 |
| ENSMUSG00000022483 | Col2a1 | collagen, type II, alpha 1 (Col2a1), mRNA | typeII | 3.6E-13 | 4.937598 |
| ENSMUSG00000026043 | Col3a1 | collagen, type III, alpha 1 (Col3a1), mRNA | typeIII | 0.442993343 | 0.681686 |
| ENSMUSG00000031502 | Col4a1 | collagen, type IV, alpha 1 (Col4a1), mRNA | type IV | 0.995426174 | 0.090912 |
| ENSMUSG00000031503 | Col4a2 | collagen, type IV, alpha 2 (Col4a2), mRNA | type IV | 0.995426174 | 0.103611 |
| ENSMUSG00000079465 | Col4a3 | collagen, type IV, alpha 3 (Col4a3), mRNA | type IV | 0.996574685 | 0.014233 |
| ENSMUSG00000067158 | Col4a4 | collagen, type IV, alpha 4 (Col4a4), mRNA | type IV | 0.989220301 | 0.464417 |
| ENSMUSG00000031274 | Col4a5 | collagen, type IV, alpha 5 (Col4a5), mRNA | type IV | 3.12E-14 | 3.130044 |
| ENSMUSG00000031273 | Col4a6 | collagen, type IV, alpha 6 (Col4a6), mRNA | type IV | 0.00000051 | 3.663765 |
| ENSMUSG00000026837 | Col5a1 | collagen, type V, alpha 1 (Col5a1), mRNA | type V | 0.000273973 | 1.73128 |
| ENSMUSG00000026042 | Col5a2 | collagen, type V, alpha 2 (Col5a2), mRNA | type V | 0.442105017 | 0.828681 |
| ENSMUSG00000004098 | Col5a3 | collagen, type V, alpha 3 (Col5a3), mRNA | type V | 0.989220301 | -0.32152 |
| ENSMUSG00000001119 | Col6a1 | collagen, type VI, alpha 1 (Col6a1), mRNA | type VI | 0.000000256 | 1.907141 |
| ENSMUSG00000020241 | Col6a2 | collagen, type VI, alpha 2 (Col6a2), mRNA | type VI | 0.0000231 | 1.60699 |
| ENSMUSG00000048126 | Col6a3 | collagen, type VI, alpha 3 (Col6a3), mRNA | type VI | 0.003193055 | 1.289803 |
| ENSMUSG00000032572 | Col6a4 | collagen, type VI, alpha 4 (Col6a4), mRNA | type VI | low expression | |
| ENSMUSG00000091345 | Col6a5 | collagen, type VI, alpha 5 (Col6a5), mRNA | type VI | 0.989220301 | 0.322323 |
| ENSMUSG00000043719 | Col6a6 | collagen, type VI, alpha 6 (Col6a6), mRNA | type VI | low expression | |
| ENSMUSG00000025650 | Col7a1 | collagen, type VII, alpha 1 (Col7a1), mRNA | type VII | 0.989220301 | -0.26505 |
| ENSMUSG00000068196 | Col8a1 | collagen, type VIII, alpha 1 (Col8a1), mRNA | type VIII | low expression | |
| ENSMUSG00000056174 | Col8a2 | collagen, type VIII, alpha 2 (Col8a2), mRNA | type VIII | 0.446143852 | 0.970351 |
| ENSMUSG00000026147 | Col9a1 | collagen, type IX, alpha 1 (Col9a1), mRNA | type IX | low expression | |
| ENSMUSG00000028626 | Col9a2 | collagen, type IX, alpha 2 (Col9a2), mRNA | type IX | 0.00000051 | 3.616545 |
| ENSMUSG00000027570 | Col9a3 | collagen, type IX, alpha 3 (Col9a3), mRNA | type IX | 0.00000014 | 3.965448 |
| ENSMUSG00000039462 | Col10a1 | collagen, type X, alpha 1 (Col10a1), mRNA | type X | low expression | |
| ENSMUSG00000027966 | Col11a1 | collagen, type XI, alpha 1 (Col11a1), mRNA | type XI | 1.04E-15 | 4.296395 |
| ENSMUSG00000024330 | Col11a2 | collagen, type XI, alpha 2 (Col11a2), mRNA | type XI | 0.00000051 | 2.899853 |
| ENSMUSG00000032332 | Col12a1 | collagen, type XII, alpha 1 (Col12a1), mRNA | type XII | 0.056573025 | 1.102192 |
| ENSMUSG00000058806 | Col13a1 | collagen, type XIII, alpha 1 (Col13a1), mRNA | type XIII | 0.996574685 | 0.015684 |
| ENSMUSG00000022371 | Col14a1 | collagen, type XIV, alpha 1 (Col14a1), mRNA | type XIV | 0.000000146 | 2.296451 |
| ENSMUSG00000028339 | Col15a1 | collagen, type XV, alpha 1 (Col15a1), mRNA | type XV | 0.989220301 | -0.18883 |
| ENSMUSG00000040690 | Col16a1 | collagen, type XVI, alpha 1 (Col16a1), mRNA | type XVI | 0.000372668 | 1.634199 |
| ENSMUSG00000025064 | Col17a1 | collagen, type XVII, alpha 1 (Col17a1), mRNA | type XVII | low expression | |
| ENSMUSG00000001435 | Col18a1 | collagen, type XVIII, alpha 1 (Col18a1), mRNA | type XVIII | 0.00000182 | 1.561112 |
| ENSMUSG00000026141 | Col19a1 | collagen, type XIX, alpha 1 (Col19a1), mRNA | type XIX | low expression | |
| ENSMUSG00000016356 | Col20a1 | collagen, type XX, alpha1 (Col20a1), mRNA | type XX | 0.99369326 | -0.12657 |
| ENSMUSG00000079022 | Col22a1 | collagen, type XXII, alpha 1 (Col22a1), mRNA | type XXII | 0.989220301 | -0.25757 |
| ENSMUSG00000063564 | Col23a1 | collagen, type XXIII, alpha 1 (Col23a1), mRNA | type XXIII | 0.995426174 | 0.053846 |
| ENSMUSG00000028197 | Col24a1 | collagen, type XXIV, alpha 1 (Col24a1), mRNA | type XXIV | low expression | |
| ENSMUSG00000058897 | Col25a1 | collagen, type XXV, alpha 1 (Col25a1), mRNA | type XXV | low expression | |
| ENSMUSG00000004415 | Col26a1 | collagen, type XXVI, alpha 1 (Col26a1), mRNA | type XXVI | low expression | |
| ENSMUSG0000004413 | Col27a1 | collagen, type XXVII, alpha 1 (Col27a1), mRNA | type XXVII | 0.010482257 | 1.417136 |
| ENSMUSG00000068794 | Col28a1 | collagen, type XXVIII, alpha 1 (Col28a1), mRNA | type XXVIII | low expression | 2.42/250 |
| ENSIVIU30000000006/94 | COIZOGI | conagen, type xxviii, aipiia 1 (C0120a1), IIIKNA | cype AAVIII | iow expression | |



Experiment as outlined in S1-A. Mice were sacrificed at E14.5 of pregnancy and placentas harvested and processed for RNA sequencing.


- (A) Gene expression of the 44 collagen genes of the mouse genome NDPI vs control.
- (B) Immunofluorescent staining of placentas for Collagen 1 (green) isolectin b4 (orange) and cell nuclei with DAPI (blue). Expression is shown in the whole placenta (left) decidual layer (middle) and labyrinth layer (right). Graphs showing quantification of the total area of Col I expression in the decidua and labyrinth. Scale bar = 2.5mm

Each symbol represents an individual mouse and statistical significance was tested by Welch's t-test (Decidua) or Student's unpaired t-test (Labyrinth). ns = not significant, $*p \le 0.05$. Data are mean \pm SEM.




- (A) Representative H&E images of E14.5 embryonic hearts from 3 independent control and 3 independent NDPI pregnancies taken at X40 magnification
- (B) Left ventricular (LV) wall thickness measurement of E14.5 embryonic hearts from control and NDPI pregnancies
- (C) Quantification of endomucin staining in E14.5 embryonic hearts shown in Figure 3A, from both groups, expressed as percentage of total heart area (bottom panel)
- (D) Staining for epicardial-specific Wilm's tumour-1 (WT-1) in E14.5 embryonic hearts from control and NDPI pregnancies
- (E) q-PCR analyses of genes expression of epicardial-specific genes, Tcf21 and Sema3d

Each symbol represents an individual mouse and statistical significance was tested by Welch's t-test (B) or Student's t-test (E). ns = not significant, *** $p \le 0.0001$. Data are mean \pm SEM.



В




- (A) Immunofluorescence staining of E14.5 embryonic hearts from control and NDPI pregnancies. Hearts were stained for Dapi (blue), smooth muscle actin (SMA; green), isolectinB4 for vessels (orange) and phosphor(p)SMAD3 (Red) Representative images shown. Scale bar =0.5 mm
- (B) Immunofluorescence staining of E14.5 embryonic hearts from control and NDPI pregnancies. Hearts were stained for Dapi (blue), smooth muscle actin (SMA; green), and transgelin (Tagln; Red). Representative images shown. Scale bar = 0.5mm

0

0


- (A) Quantification of number and length of left ventricular (LV) trabeculae analysed from HREM images. Scale bar = 0.5mm
- (B) Analyses of proportion of proliferating cells within E14.5 embryonic hearts using phosohistone H3 (pH3). Scale bar = 0.5mm
- (C) CD31+ endothelial cells from hearts of E14.5 embryos were analyzed for the expression of ICAM1, ICAM2, Endoglin, VEGFR1 and THSD1. Quantification showing the median fluorescent intensity (MFI) of the corresponding surface marker.

Each symbol represents an individual embryonic hearts from distinct pregnancies and statistical significance was tested by unpaired Student's t-test . ns = not significant, *p \leq 0.05, ** p \leq 0.01, ***p \leq 0.001 **** p \leq 0.0001. In all cases, data are mean \pm SEM.



- (A) Flow cytometric and immunofluorescent analyses of placentas from *In vivo* transfer of GFP⁺ leukocytes in Control and NDPI pregnancies at E14.5. Images taken at x20 magnification and x200 magnification (dotted lined box)
- (B) Flow cytometric and immunofluorescent analyses of embryonic hearts from *In vivo* transfer of GFP+ leukocytes in isotype and NDPI pregnancies at E14.5. Images taken at x20 magnification and x200 magnification (dotted lined box)
- (C) Immunofluoresnce images of placentas from *In vivo* FITC-dextran infusion for 1 hour prior to sacrifice from isotype and NDPI pregnancies at E14.5. Images taken at x20 magnification and x200 magnification (dotted lined box).


Scale bar = 0.5mm Each symbol represents an individual mouse and statistical significance was tested by unpaired Student's t-test (placenta) or Welch's t-test (embryo heart). ns = not significant, $p \le 0.05$, ** $p \le 0.01$, *** $p \le 0.001$ **** $p \le 0.0001$. In all cases, data are mean $p \le 0.001$.



- (A) Median fluorescent intensity of MHCII, CCR2, CXCR2, CCR5 and CCR6 on maternal F4/80+Ly6Chi cells found in embryo hearts. Lower panel, representative histograms.
- (B) Violin plot showing gene expression of chemokines in embryo hearts from control and NDPI pregnancies normalized to control
- (C) Graph showing gene expression of CCL2, CCL3, CCL4 and CXCL2 in embryo livers from neutrophil depleted pregnancies normalised to isotype control.
- (D) Violin plot showing gene expression of cytokines in embryo hearts from control and NDPI pregnancies normalized to control
- (E) Representative FACs plot showing non leukocytes, maternal leukocytes (CD45.1+ CD45.2-) and fetal cells (CD45.1+CD45.2+) in embryo heart. Graphs show quantification of number of cells in maternal or fetal origin leukocytes or from non-leukocytes expressing II-1β and IL-6.

Each symbol represents an individual mouse and statistical significance was tested by unpaired Student's t-test or Welch's t-test (CCR5, CXCR4 in A; CCL4 in B; and Maternal IL-1b and IL-6, Fetal IL-1b and non-leukocyte IL-1b and IL-6 in E). ns = not significant, *p \leq 0.05, ** p \leq 0.01, ***p \leq 0.001 **** p \leq 0.0001. In all cases, data are mean \pm SEM.


C



- (A) Comparison of E14.5 placenta weights from Control, NDPI, CCR2+/-control and CCR2+/- NDPI pregnancies
- (B) Comparison of E14.5 placenta TNF- α production, as measured by standard ELISA, from Control, NDPI, CCR2+/-control and CCR2+/- NDPI pregnancies
- (C) Quantification of total CD45+ leukocytes by flow cytometry in E14.5 placentas from Control, NDPI, CCR2+/-control and CCR2+/- NDPI pregnancies. Numbers are quantified as per gram of placenta tissue
- (D) Representative FACS plots of F4/80 and Ly6c populations in CCR2+/-control and CCR2+/-NDPI placentasLoxl2 (compare with isotype and NDPI plots shown in Figure 1H); Comparison of F4/80+Ly6Chi macrophage and F4/80-Ly6Chi monocyte populations within the placenta from NDPI, CCR2+/-control and CCR2+/-NDPI pregnancies with Control. Numbers expressed as per gram of placenta tissue
- (E) RT (q) PCR analyses of key heart development genes from E14.5 embryo hearts of Control, NDPI, CCR2+/-control and CCR2+/-NDPI pregnancies. Data compare gene transcription changes from embryonic hearts of NDPI, CCR2+/-control and CCR2-/- NDPI pregnancies to Control.
- (F) Flow cytometric analyses of resident fetal CX3CR1+CCR2- macrophage proliferation, measured by *in vivo* BrdU incorporation. Data compare proliferation from embryonic hearts of NDPI, CCR2+/-control and CCR2+/- NDPI pregnancies compared to Control.

Each symbol represents an individual mouse and statistical significance was tested one-way ANOVA or Brown-Forsythe test (A, B and D), with Dunnett's multiple comparison test. ns = not significant, $p \le 0.05$, ** $p \le 0.01$, *** $p \le 0.001$ **** $p \le 0.0001$. In all cases, data are mean \pm SEM.

Figure S9






Neutrophils were depleted at day 4.5 and 7.5 of pregnancy using α Ly6G. Mice were sacrificed at E14.5 of pregnancy and hearts dissected from harvested embryos from control or neutrophil depleted placental inflammation (NDPI) pregnancies. CD45⁺ cells were isolated from heart single cell suspensions using CD45 PE and anti-PE microbeads. Single cell sequencing was performed on the isolated cells.

Heat map of single-cell gene expression data across all clusters


| Cluster number | Cell type | Top genes |
|----------------|-------------------------------|----------------------------------------------------------------------------------------------------------------------------|
| 0 | Resident Fetal Macrophages | See figure 5 C |
| 1 | Macrophage 1 | AY036118 Hist1h4d Lars2 Hist1h1b Snx6 Dab2 Ftl1 Aif1 Ckb Plin2 Serpinb6a Ighm |
| 2 | Macrophage 2 | Hist1h1b Snx6 Dab2 Ftl1 Aif1 Ckb Plin2 Serpinb6a Ighm Wwp1 Rnase4 Adrb2 Adamts1 Tmx4 Ccl12 Hspa1a Ednrb Hgsnat Ccl7 |
| 3 | Maternal leukocytes | See figure 5 C |
| 4 | T cells | Fgfbp1 Tcrg-C2 Gm4632 Myl10 Ptcra 9130015A21Rik Gm525 Notch1 Kcnq1ot1 Bcl11b Tcf12 Atp8a1 Arpp21 Fam169b Cd3g Gzma Akr1c13 |
| 5 | Endothelial 1 | Mfap2 Unc5c Rbp1 Nfib Ccl11 Col3a1 Meg3 Tbx2 Notch1 |
| 6 | NKT cells | Notch1 Kcnq1ot1 Bcl11b Tcf12 Atp8a1 Arpp21 Fam169b Satb1 Themis Cd3g Gzma Akr1c13 Rgcc 1500009L16Rik Akr1c12 Tcf7 |
| 7 | Unknown | II18 Nr1h3 Sdc3 Hmox1 Fth1 Gclm |
| 8 | Unknown | Hmox1 Fth1 Gclm Srxn1 Cd36 Sqstm1 Clec4n Hspb1 Clec4d |
| 9 | Neutrophil 1 | Mpo Serpinb1a Prtn3 Cebpe Ctsg Ms4a3 Elane Tmed3 Fcnb Alas1 |
| 10 | T cell 2 | Alas1 Trbc2 Cd3g Gzma Akr1c13 Rgcc 1500009L16Rik Akr1c12 Tcf7 Khdc1a Agfg1 |
| 11 | Bcell 2 | Klrd1 Cd7 Il2rb Cd160 AW112010 Ccl5 Ifng Ncr1 Klrc1 |
| 12 | B cell 1 | Angpt1 Fasl Tnfrsf23 Dusp2 Cox4i2 Olfr1369-ps1 Dqx1 Myo1c Clec1b Ctla2a Nrgn Gng11 Cd9 |
| 13 | Mast cell 1 | Tpsb2 Cpa3 Tpsab1 Hdc Kit II1rl1 Tph1 Cma1 Prss34 Rgs13 |
| 14 | Unknown | lsg15 lfi44 lrf7 |
| 15 | Macrophage 3 | Irf7 Ermap Car2 Rhd Icam4 Alad Cpox Mt2 Bex4 |
| 16 | Unknown | Gm26917 Ints6l Raph1 Tmcc1 Pid1 Chka Nfkbi |
| 17 | Myeloid origin | Snca Gypa Hbb-bt Mkrn1 Hba-a2 Bpgm Fam46c Slc25a37 |
| 18 | Dendritic Cells | H2-Aa H2-Ab1 H2-Eb1 Cd74 H2-DMb1 Tnni2 Cd209a Plbd1 Adra2a |
| 19 | Neutrophil 2 | Stfa2 Lcn2 Wfdc21 Stfa2l1 Olfm4 Stfa3 Ltf Ngp Retnlg |
| 20 | Monocyte/macroph age | Fcna Ccl6 Trf Ltc4s Vsig4 Smpdl3a Apoc1 Fn1 |
| 21 | Endothelial 2 | Cldn5 Esam Egfl7 Ramp2 Emcn Cyyr1 Robo4 Plvap Aplnr |
| 22 | Endothelial-like 1 | Clec1b Ctla2a Nrgn Gng11 Cd9 Gp5 Vwf |
| 23 | Mast cell 2 | Cd200r3 Cyp11a1 Acod1 Lilr4b Mcpt8 Ccl9 Csf2rb Selenom Grm6 |
| 24 | Unknown | Hbb-bh1 Hba-x Hbb-y Hba-a1 |
| 25 | Endothelial-like 2 | Mal2 Rassf9 Epcam Fgfr2 Lypd2 Cytl1 Myh14 Smim22 |

Data in the table indicate top genes expressed in each cluster of the single-cell analyses, as described in Figure S9. These genes were used to identify the cell types for each of the clusters



- (A) Neutrophils were depleted at day 4.5 and 7.5 of pregnancy using αLy6G. Offspring of these dams were sacrificed at post-natal day 5 (P5) or 28 as indicated and heart structure and immune composition assessed. Offspring from Control (white) and neutrophil depleted (NDPI) (pink). P5 offspring body weights in grams and heart: body weight ratio.
- (B) Flow cytometry plots of leukocytes in postnatal day 5 hearts from control of NDPI pregnancies; CD45.1+ CD45.2- cells are of maternal origin and CD45.1+CD45.2+ cells are of fetal origin. Graph comparing number of maternal cells in offspring hearts at E14.5 and P5.
- (C) Flow cytometric analyses of CX3CR1+ macrophages of fetal origin in P5 offspring hearts from isotype and NDPI pregnancies expressed as per gram of heart tissue. Representative flow cytometry plots shown.
- (D) Proportion of CCR2+ and CCR2- cells within the total population of CX3CR1+ macrophages in P5 heart
- (E) Representative immunofluorescent images showing the expression of endomucin and wheat germ agglutinin in transverse sections of hearts from P5 offspring from control or NDPI x20 magnification. Scale bar 1mm. Magnified (x200) images showing endomucin staining of the ventricles (LV -left; RV, right). Graph showing the proportion of total heart area expressing endomucin. Hearts show Dapi (blue) wheat germ agglutinin (green) and endomucin (orange). Scale bar = 1mm
- (F) Representative FACS plots showing heart CD31 $^+$ populations from P5 offspring from dams treated with either isotype control or α Ly6G neutralizing antibody. Graphs showing the number of CD31 $^+$ cells per gram of heart tissue and the number of these CD31 $^+$ cells expressing ICAM-1, Endoglin and VEGFR1.
- (G) Longitudinal sections of offspring P5 hearts from isotype, NDPI, CCR2+/-control and CCR2+/-NDPI pregnancies. Hearts show Dapi (blue), wheat germ agglutinin (WGA; green) and endomucin (orange). X20 magnification


Each symbol represents an individual mouse and statistical significance was tested Student's unpaired t-test (A and C), Brown-Forsythe test with Dunnett's multiple comparison test (D). Welch's t-test (B, E and F -CD31), Mann-Whitney test (F- VEGFR1). ns = not significant, *p \leq 0.05, ** p \leq 0.01, ***p \leq 0.001 **** p \leq 0.0001. In all cases, data are mean \pm SEM.



- (A) Dampening of exaggerated placental inflammation schematic for experimental design.
- (B) Weights of E14.5 placentas ELISA showing the concentration of TNF- α in placenta digest supernatants. Control treated (white), neutrophil depleted (NDPI) (pink), neutrophil depleted TNF α neutralised (NDPI + aTNF α) (blue).
- (C) Immunofluorescent staining of placentas for wheat germ agglutinin (WGA) (green) to show gross structure and cell nuclei with DAPI (blue). White dotted line indicates the separation of the labyrinthine zone/trophoblast area and the outer junctional zone. Graph showing the proportion of the total area of the placentas occupied by the trophoblast zone. Scale bar =2.5mm
- (D) RT-PCR showing the gene expression of Col1a1, col1a2 and col4a6 in placentas from control and NDPI and NDPI + aTNFa pregnancies normalised to control.
- (E) Immunofluorescent staining of placentas for Collagen I (green) isolectin b4 (orange) and cell nuclei with DAPI (blue) (left image) or Collagen IV isolectin b4 (orange) and cell nuclei with DAPI (blue) (right image). Graphs showing quantification of the total area of Col I or Col IV expression in the decidua and labyrinth. Scale bar = 2.5mm
- (F) Absolute number of neutrophils expressing TNF α , CXCR2, CD114 and MMP9 from placentas analyzed by flow cytometry expressed as absolute cell number per gram of tissue.
- (G) Inflammatory monocytes from placentas analyzed by flow cytometry expressed as absolute cell number per gram of tissue.
- (H) Representative FACS plots showing fetal and maternal leukocytes in embryo heart and graph showing quantification of number of maternal leukocytes per embryo heart.
- (I) Proportion of total cells in embryo heart expressing CX3CR1+CCR2+, CX3CR1+CCR2- or CX3CR1-CCR2-.
- (J) Violin plot showing gene expression of IL-1 β and IL-6 in embryo hearts from control and NDPI pregnancies normalized to control.
- (K) Flow cytometric analyses of endothelial (CD45-CD31+) and cardiomyocyte (CD45-Troponin-T+) proliferation, as measured by in vivo BrdU incorporation from E14.5 embryonic hearts of isotype, NDPI and NDPI+aTNFa pregnancies
- (L) Proportion of CCR2+ and CCR2- CX3CR1+ macrophages from P5 offspring hearts from isotype, NDPI and NDPIaTNFα pregnancies
- (M) Comparison of heart: body weight rations from P5 offspring of isotype, NDPI and NDPIaTNF α pregnancies
- (N) Offspring from treated pregnancies sacrificed at day 28 post-natal. Gating strategy and representative FACS plots of heart cells based on expression of F4/80 and Ly6C. Graphs showing the proportion of various F4/80 Ly6C subpopulations and absolute number per gram of heart tissues. Proportion of MHCII, and CCR2 (%) within F4/80+Ly6C+ population from P28 hearts.

Each symbol represents an individual mouse and statistical significance was tested using one-way ANOVA with Bonferroni multiple comparison test (B-E and J,M, and N (bar graph), Brown-Forsythe test with Dunnett's multiple comparison test (F and K) or two-way ANOVA, comparing means of CCR2+ or CCR2- % between mouse groups with Tukey's multiple comparison test (I and L). ns = not significant, *p \leq 0.05, ** p \leq 0.01, ***p \leq 0.001 in all cases, data are mean \pm SEM

A Figure S13



| |) |
|---|---|
| _ | |

| Primary Antibodies | Cat# and RFID | Company |
|------------------------------------------------------------|---------------------------------|-------------------|
| Anti-Mouse CD45.1, APC Cy7 (clone: A20) | 110716; RRID: AB_313505 | Biolegend |
| Anti-Mouse CD45.2, BV605 (clone: 104) | 10984; RRID:AB_2563485 | Biolegend |
| Anti-Mouse CD45.2, PE (clone: 104) | 109808; RRID:AB_313445 | Biolegend |
| Anti-Mouse CD45, PE (clone: 30 F11) | 103106; RRID:AB_312971 | Biolegend |
| Anti-Mouse Ly-6C, PE Cy7 (clone: HK1.4) | 128018; RRID:AB_1732082 | Biolegend |
| Anti-Mouse F4/80, PE (clone: BM8) | 123110; RRID:AB_893486 | Biolegend |
| Anti-Mouse F4/80, APC (clone: BM8) | 123116; RRID:AB_893481 | Biolegend |
| Anti-Mouse F4/80, PerCP Cy5 (clone: BM8) | 123128; RRID:AB_893484 | Biolegend |
| Anti-Mouse CX3CR1, PerCP Cy5 (clone: SA011F11) | 149009; RRID:AB_2564493 | Biolegend |
| Anti-Mouse CX3CR1, APC (clone: SA011F11) | 149008; RRID:AB_2564493 | Biolegend |
| Anti-Mouse MHC II (I-Ab), FITC (clone: AF6-120.1) | 116406; RRID:AB_313725 | Biolegend |
| Anti-Mouse Mertk, AF700 (clone: DS5MMER) | 56-5751-80; RRID:AB_2784770 | Invitrogen |
| Anti-Mouse CCR2, BV421 (clone: SA203G11) | 150605; RRID:AB_2571913 | Biolegend |
| Anti-Mouse CCR6, BV605 (clone: 29-2L17) | 129819; RRID:AB_2562513 | Biolegend |
| Anti-Mouse CCR5, AF488 (clone: HM-CCR5) | 107008; RRID:AB_528756 | Biolegend |
| Anti-Mouse CXCR2, PerCP Cy5 (clone: SA044G4) | 149308; RRID:AB_2565696 | Biolegend |
| Anti-Mouse Ly-6G, PE (clone: 1A8) | 127608; RRID:AB_1186099 | Biolegend |
| Anti-Mouse Ly-6G, AF700 (clone: 1A8) | 127622; RRID:AB_1064326 9 | Biolegend |
| Anti-Mouse CD3, AF700 (clone: 17A2) | 56-0032-82; RRID:AB_529507 | Invitrogen |
| Anti-Mouse CD4, Super Bright 780 (clone: RM4-5) | 78-0042-82; RRID:AB_2722967 | Invitrogen |
| Anti-Mouse NK1.1, AF647 (clone: PK136) | 108720; RRID:AB_2132713 | Biolegend |
| Anti-Mouse CCR2, BV421 (clone: SA203G11) | 150605; RRID:AB_2571913 | Biolegend |
| Anti-Mouse IL-1β, FITC (clone: NJTEN3) | 11-7114-80; RRID:AB_1071883 | Invitrogen |
| Anti-Mouse IL-6, PE (clone: MP5 20F3) | 504503; RRID:AB_315337 | Biolegend |
| Anti-Mouse TMTSP (THSD1), Purified (clone: TX17.10) | 122102;RRID:AB_8 30887 | Biolegend |
| Anti-Mouse Goat anti-rat lgG, PE Cy7 (clone: Poly4054) | 405413'RRID:AB_1 0661733 | Biolegend |
| Anti-Mouse CD54 (ICAM1), PerCP Cy5.5 (clone: YN1/1.7.4) | 116123; RRID:AB_2715951 | Biolegend |
| Anti-Mouse CD102 (ICAM2), AF488 (clone: 3C4(MIC2/4)) | 105609; RRID:AB_2264501 | Biolegend |
| Anti-Mouse CD31, AF700 (clone: 390) | 102444;RRID:AB_2 832289 | Biolegend |
| Anti-Mouse CD105 Endoglin, Pacific Blue (clone: MJ7/18) | 120411; RRID:AB_2098890 | Biolegend |
| Anti-Mouse VEGFR1, PE (clone: 141522) | FAB4711P; RRID:AB_2107040 | R&D systems |
| Anti-Mouse TropT, APC (clone: 13-11) | 565744; RRID:AB_2739341 | BD Biosciences |
| Anti-Mouse CD11b, PE (clone: M1/70) | 101208; RRID:AB_312791 | Biolegend |
| Anti-Mouse CD11b, BV605 (clone: M1/70) | 101257; RRID:AB_2565431 | Biolegend |
| Anti-Mouse CD62L, PE Cy7 (clone: MEL-14) | 104418; RRID:AB_313103 | Biolegend |
| Anti-Mouse CD114, FITC (clone: 723806) | FAB6039G | R&D systems |

D

| Primary Antibodies | Cat# | Company |
|-----------------------------------------------|-------------|-----------------|
| Rabbit polyclonal to CD31 | ab28364 | Abcam |
| Rat monoclonal [V.7C7.1] Endomucin | ab106100 | Abcam |
| Monoclonal Anti-Actin, α-Smooth Muscle - FITC | F37772ML | Sigma |
| Rat anti-mouse CD45 Antibody [30-F11] | 103101 | BioLegend |
| Wheat Germ Agglutinin Alexa Fluor 488 | W11261 | Thermofisher |
| Wheat Germ Agglutinin Alexa Fluor 647 | W32466 | Thermofisher |
| Rabbit Collagen I AF488 | NBP1-77 458 | Novus Bio |
| Collagen IV | NBP120-6586 | Novus Bio |
| Isolectin B4 | B-1205 | Vector |
| Anti-phospho histone H3 AF647 | 06-570 | Merck Millipore |
| Transgelin rabbit polyclonal | Ab14106 | Abcam |
| WT1 rabbit polyclonal | 12609-1 | Proteintech |
| Secondary Antibodies | Cat# | Company |
| Streptavidin alexa fluor 555 | S32355 | Thermofisher |
| Donkey anti-Rat lgG (H+L) Alexa Fluor 555 | A48270 | Thermofisher |
| Donkey anti-Rabbit lgG (H+L) Alexa Fluor 647 | A-31573 | Thermofisher |
| Hoechst 33342 | Ab228551 | Abcam |
| | | |

| Probe | Forward sequence (5' to 3') | Reverse Sequence (5' to 3') |
|----------|-----------------------------|-----------------------------|
| Col 1 a1 | GCTCCTCTTAGGGGCCACT | CCACGTCTCACCATTGGGG |
| Col 1 a2 | GTAACTTCGTGCCTAGCAACA | CCTTTGTCAGAATACTGAGCAGC |
| Col2a1 | CAGGATGCCCGAAAATTAGGG | ACCACGATCACCTCTGGGT |
| Col4a5 | GTCCACCAGGTACAGAAGGTC | CTCCTTTCAAACCAGGTAAGCC |
| Col 4a6 | ATCGGATACTCCTTCCTCATGC | CCAGGGGAGACTAGGGACTG |
| col 9A1 | CGACCGACCAGCACATCAA | AGGGGACCCTTAATGCCT |
| Col 9A2 | AAGGGCCTCCAGGTAAAGTT | TCCCATTAAACCATCAATGCCA |
| Col 9A3 | GGAATGCCGGGGTTCAAGG | AGTCCTCTTAATCCTCGTGGG |
| Cxcl1 | CTGGGATTCACCTCAAGAACATC | CAGGGTCAAGGCAAGCCTC |
| CXCL2 | CCAACCACCAGGCTACAGG | GCGTCACACTCAAGCTCTG |
| CXCL5 | GTTCCATCTCGCCATTCATGC | GCGGCTATGACTGAGGAAGG |
| CCL2 | TTAAAAACCTGGATCGGAACCAA | GCATTAGCTTCAGATTTACGGGT |
| CCL3 | TTCTCTGTACCATGACACTCTGC | CGTGGAATCTTCCGGCTGTAG |
| CCL4 | TTCCTGCTGTTTCTCTTACACCT | CTGTCTGCCTCTTTTGGTCAG |
| CXCL12 | TGCATCAGTGACGGTAAACCA | CACAGTTTGGAGTGTTGAGGAT |
| RPL32A | TTAAGCGAAACTGGCGGAAAC | TTGTTGCTCCCATAACCGATG |
| IL-6 | TAGTCCTTCCTACCCCAATTTCC | TTGGTCCTTAGCCACTCCTTC |
| TNF-α | CATCTTCTCAAAATTCGAGTGACAA | TGGGAGTAGACAAGGTACAACCC |
| HPRT | GTAATGATCCAGTCAACGGGGGAC | CCAGCAAGCTTGCAACCTTAACCA |
| II-10 | AAACAAAGGACCAGCTGGAC | TTCCGATAAGGCTTGGCAAC |
| IL-1 | AACCTGCTGGTGTGACGTTC | CAGCACGAGGCTTTTTTGTTGT |
| Gata4 | CCCTACCCAGCCTACATGG | ACATATCGAGATTGGGGTGTCT |
| Gata4 | TTGCTCCGGTACAGCAGTG | GTGGTCGCTTGTGTAGAAGGA |
| Mef2c | ATGCCATCAGTGAATCAAAGGAT | GTGGTACGGTCTCCCAACT |
| Hey2 | AAGCGCCCTTGTGAGGAAAC | GGTAGTTGTCGGTGAATTGGAC |
| Lox/2 | ATTAACCCCAACTATGAAGTGCC | CTGTCTCCTCACTGAAGGCTC |
| Myh6 | GCCCAGTACCTCCGAAAGTC | GCCTTAACATACTCCTCCTTGTC |
| Myh7 | ACTGTCAACACTAAGAGGGTCA | TTGGATGATTTGATCTTCCAGGG |
| Nppa | GCTTCCAGGCCATATTGGAG | GGGGCATGACCTCATCTT |
| Nppb | GAGGTCACTCCTATCCTCTGG | GCCATTTCCTCCGACTTTTCTC |
| Yap1 | ACCCTCGTTTTGCCATGAAC | TGTGCTGGGATTGATATTCCGTA |
| Tcf21 | CCCACTAAGAAAAGCCCGCTC | CCGTTCTCGTACTTGTCGTTC |
| Sema3d | CTGTATCCCCTTTTTGGGTTCAT | AACCAGACTGAGCAGGAAGAC |

- (A) Flow cytometry gating strategy used for all flow cytometry data. Figure shows strategy of gating on singlet and live cells (based on live/dead stain)
- (B) Flow cytometry antibody resource table
- (C) Immunofluorescence antibody resource table
- (D) Forward and reverse sequences of all primers used in the paper